Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

1.

Eribulin in heavily pretreated metastatic breast cancer patients and clinical/biological feature correlations: impact on the practice.

Fabi A, Moscetti L, Ciccarese M, Caramanti M, Salesi N, La Verde N, Russillo M, Generali D, Scandurra G, Vari S, Pacetti U, Cognetti F, Giannarelli D.

Future Oncol. 2015;11(3):431-8. doi: 10.2217/fon.14.271.

PMID:
25675124
2.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V.

J Clin Oncol. 2015 Jan 20. pii: JCO.2014.57.1794. [Epub ahead of print]

PMID:
25605838
3.

Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.

Sanna G, Fabi A, Crivellari D, Saracchini S, Battelli N, Nisticò C, Capobianco AM, Zampa G, Bottini A, Del Prete S, Simoncini E, Galli A, Matasconi M, Restuccia E, Biganzoli L.

Tumori. 2014 Jul-Aug;100(4):432-8. doi: 10.1700/1636.17904.

PMID:
25296593
4.

Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.

Vaccaro V, Fabi A, Vidiri A, Giannarelli D, Metro G, Telera S, Vari S, Piludu F, Carosi MA, Villani V, Cognetti F, Pompili A, Marucci L, Carapella CM, Pace A.

Biomed Res Int. 2014;2014:351252. doi: 10.1155/2014/351252. Epub 2014 May 4.

5.

Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic.

Fabi A, Mottolese M, Segatto O.

J Mol Med (Berl). 2014 Jul;92(7):681-95. doi: 10.1007/s00109-014-1169-7. Epub 2014 May 28. Review.

PMID:
24861025
6.

Weight of epilepsy in brain tumor patients.

Maschio M, Sperati F, Dinapoli L, Vidiri A, Fabi A, Pace A, Pompili A, Carapella CM, Cantelmi T.

J Neurooncol. 2014 Jun;118(2):385-93. doi: 10.1007/s11060-014-1449-7. Epub 2014 May 1.

PMID:
24789254
7.

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study.

Gamucci T, Michelotti A, Pizzuti L, Mentuccia L, Landucci E, Sperduti I, Di Lauro L, Fabi A, Tonini G, Sini V, Salesi N, Ferrarini I, Vaccaro A, Pavese I, Veltri E, Moscetti L, Marchetti P, Vici P.

J Cancer. 2014 Mar 20;5(5):320-7. doi: 10.7150/jca.8748. eCollection 2014.

8.

Summer heat and low soil organic matter influence severity of hazelnut Cytospora canker.

Lamichhane JR, Fabi A, Varvaro L.

Phytopathology. 2014 Apr;104(4):387-95. doi: 10.1094/PHYTO-05-13-0136-R.

9.

Effect of adjuvant trastuzumab treatment in conventional clinical setting: an observational retrospective multicenter Italian study.

Campiglio M, Bufalino R, Sasso M, Ferri E, Casalini P, Adamo V, Fabi A, Aiello R, Riccardi F, Valle E, Scotti V, Tabaro G, Giuffrida D, Tarenzi E, Bologna A, Mustacchi G, Bianchi F, Balsari A, Ménard S, Tagliabue E.

Breast Cancer Res Treat. 2013 Aug;141(1):101-10. doi: 10.1007/s10549-013-2658-z. Epub 2013 Aug 13.

10.

An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study.

Lazzaro C, Bordonaro R, Cognetti F, Fabi A, De Placido S, Arpino G, Marchetti P, Botticelli A, Pronzato P, Martelli E.

Clinicoecon Outcomes Res. 2013 Apr 11;5:125-35. doi: 10.2147/CEOR.S41850. Print 2013.

11.

Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.

Pacetti U, Veltri E, Fattoruso SI, Cardillo FD, Evangelista S, Cognetti F, Fabi A.

Anticancer Res. 2013 Apr;33(4):1721-4.

PMID:
23564822
12.

Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.

Del Mastro L, Fabi A, Mansutti M, De Laurentiis M, Durando A, Merlo DF, Bruzzi P, La Torre I, Ceccarelli M, Kazeem G, Marchi P, Boy D, Venturini M, De Placido S, Cognetti F.

BMC Cancer. 2013 Mar 28;13:164. doi: 10.1186/1471-2407-13-164.

13.

Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease.

Telera S, Fabi A, Pace A, Vidiri A, Anelli V, Carapella CM, Marucci L, Crispo F, Sperduti I, Pompili A.

J Neurooncol. 2013 Jun;113(2):313-25. doi: 10.1007/s11060-013-1120-8. Epub 2013 Mar 25.

PMID:
23525948
14.

Epidermal growth factor receptor gene copy number may predict lapatinib sensitivity in HER2-positive metastatic breast cancer.

Fabi A, Merola R, Ferretti G, Di Benedetto A, Antoniani B, Ercolani C, Nisticò C, Papaldo P, Ciccarese M, Sperduti I, Vici P, Marino M, Gori S, Botti C, Malaguti P, Cognetti F, Mottolese M.

Expert Opin Pharmacother. 2013 Apr;14(6):699-706. doi: 10.1517/14656566.2013.779672. Epub 2013 Mar 9.

PMID:
23472669
15.

Epidemiological study of hazelnut bacterial blight in central Italy by using laboratory analysis and geostatistics.

Lamichhane JR, Fabi A, Ridolfi R, Varvaro L.

PLoS One. 2013;8(2):e56298. doi: 10.1371/journal.pone.0056298. Epub 2013 Feb 12.

16.

An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting.

Fabi A, Malaguti P.

Expert Opin Pharmacother. 2013 Apr;14(5):629-41. doi: 10.1517/14656566.2013.771166. Epub 2013 Feb 18. Review.

PMID:
23414148
17.

The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.

Malaguti P, Vari S, Cognetti F, Fabi A.

Anticancer Res. 2013 Jan;33(1):21-8. Review.

PMID:
23267124
18.

Effect of pregabalin add-on treatment on seizure control, quality of life, and anxiety in patients with brain tumour-related epilepsy: a pilot study.

Maschio M, Dinapoli L, Sperati F, Pace A, Fabi A, Vidiri A, Pompili A, Carapella CM.

Epileptic Disord. 2012 Dec;14(4):388-97. doi: 10.1684/epd.2012.0542.

PMID:
23248037
19.

Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy.

Fabi A, Russillo M, Ferretti G, Metro G, Nisticò C, Papaldo P, De Vita F, D'Auria G, Vidiri A, Giannarelli D, Cognetti F.

BMC Cancer. 2012 Oct 19;12:482. doi: 10.1186/1471-2407-12-482.

20.

Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer.

Minuti G, Cappuzzo F, Duchnowska R, Jassem J, Fabi A, O'Brien T, Mendoza AD, Landi L, Biernat W, Czartoryska-Arłukowicz B, Jankowski T, Zuziak D, Zok J, Szostakiewicz B, Foszczyńska-Kłoda M, Tempińska-Szałach A, Rossi E, Varella-Garcia M.

Br J Cancer. 2012 Aug 21;107(5):793-9. doi: 10.1038/bjc.2012.335. Epub 2012 Jul 31.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk